HCC Clinical Trial
Official title:
Prospective Evaluation of Local Tumor Progression After Radiofrequency Ablation of Hepatocellular Carcinoma: Effectiveness of Immediate Second-Look Evaluation Using Pre-RFA MRI and Post-RFA CT Registration
Verified date | December 2016 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Observational |
Magnetic resonance imaging (MRI) has been widely used for small liver lesion detection and characterization. In patients who undergo RFA, MRI is often performed before RFA, whereas immediate technical success is usually assessed by CT. Conventional visual assessment of two modalities may be more challenging than being anticipated, because acquisition position, respiration, and spatial resolution differ between the two. Therefore, the study purpose is to evaluate the results of software-assisted ablative margin assessment using registration of different pre-and post-RFA modalities compared with the conventional method of side-by-side MRI-CT comparison in patients with HCCs.
Status | Completed |
Enrollment | 77 |
Est. completion date | October 2016 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patients (= 18 years) who were referred to our radiology department for liver tumor RFA - patients who had liver MR images of sufficient quality for pre-RFA evaluation within 30 days before RFA - patients with 1-3 tumors (<5 cm) Exclusion Criteria: - Child-Pugh class C - any uncorrected coagulopathy - hypersensitivity to iodine or other reasons that prevented the performance of post-RFA contrast-enhanced CT |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Local tumor progression (LTP) | 5-year-LTP rate in HCC between sufficient and insufficient ablative margin groups (according to visual assessment and registration software-assisted assessment) | 60 months | No |
Secondary | technique efficacy | Rate of absence of viable tumor on 1-months follow-up CT scan. | 1 month after RFA | No |
Secondary | immediate technical success on visual assessment | technical success of RFA on post-RFA CT using side-by-side comparison of pre-RFA MRI and post-RFA CT | 1 day after RFA | No |
Secondary | immediate technical success on registration-software assessment | technical success of RFA on post-RFA CT using registration-software assessment between pre-RFA MRI and post-RFA CT | 1 day after RFA | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05458115 -
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
|
||
Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06434480 -
SBRT in HCC With Oligoprogression on Atezo-Bev
|
N/A | |
Completed |
NCT04542837 -
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05025592 -
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
|
||
Completed |
NCT04172506 -
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05840133 -
Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
|
||
Not yet recruiting |
NCT06024252 -
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
|
||
Terminated |
NCT02785874 -
Statin With Palliative Therapy for HCC
|
N/A | |
Not yet recruiting |
NCT02715492 -
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
|
Phase 3 | |
Not yet recruiting |
NCT06069947 -
SALT for Liver Cirrhosis With HCC
|
N/A | |
Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Suspended |
NCT02935478 -
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
|
N/A | |
Recruiting |
NCT05592171 -
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
|
N/A | |
Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
Recruiting |
NCT05544253 -
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT06184152 -
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
|
||
Completed |
NCT02675920 -
A Study of HCC High Risk Group Using Two Surveillance Tools
|
||
Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A |